-
公开(公告)号：US20110195904A1
公开(公告)日：2011-08-11
申请号：US13080051
申请日：2011-04-05
CPC分类号： G09G3/3233 , G09G2300/0452 , G09G2300/0465 , G09G2300/0804 , G09G2300/0819 , G09G2300/0852 , G09G2300/0861 , G09G2310/0235 , G09G2310/0251 , G09G2320/043 , H01L27/3211 , H01L27/3244
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US20090054341A1
公开(公告)日：2009-02-26
申请号：US12247141
申请日：2008-10-07
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US08759291B2
公开(公告)日：2014-06-24
申请号：US13080051
申请日：2011-04-05
IPC分类号： A61K38/22 , C07K14/575
CPC分类号： G09G3/3233 , G09G2300/0452 , G09G2300/0465 , G09G2300/0804 , G09G2300/0819 , G09G2300/0852 , G09G2300/0861 , G09G2310/0235 , G09G2310/0251 , G09G2320/043 , H01L27/3211 , H01L27/3244
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US07442680B2
公开(公告)日：2008-10-28
申请号：US10656093
申请日：2003-09-05
IPC分类号： A61K38/26
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US06703359B1
公开(公告)日：2004-03-09
申请号：US09622105
申请日：2000-09-22
IPC分类号： A01N3718
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia,such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US20050037958A1
公开(公告)日：2005-02-17
申请号：US10656093
申请日：2003-09-05
申请人： Andrew Young , Will Vine , Nigel Beeley , Kathryn Prickett
发明人： Andrew Young , Will Vine , Nigel Beeley , Kathryn Prickett
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US07928065B2
公开(公告)日：2011-04-19
申请号：US12247141
申请日：2008-10-07
IPC分类号： A61K38/22 , C07K14/575
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.03 秒)